-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer
We are conducting a clinical trial to test a new combination of four drugs for treating pancreatic cancer. Our research in the lab has shown ...
-
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
The purpose of this study is to understand whether potential new drugs, AB680 and AB122, can be safely given to patients with pancreatic cancer in ... -
A Phase 1b Study to Evaluate the Safety Tolerability and Preliminary Efficacy of ATP150/ATP152 VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
This study is designed for patients with resected KRAS G12D/G12V mutated pancreatic cancer.This is an open-label, phase 1b study comprising of two parts ...
-
A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and NabPaclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
This study is investigating the combination of CA-4948 and gemcitabine/nab-paclitaxel chemotherapy to find the highest dose that patients can take who have adenocarcinoma of ... -
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies
This is a study to test a new medicine called CDX-585 on patients with advanced or spreading solid tumors that have not improved with current ...
-
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
This study is for adults who have advanced solid tumors that lack a certain enzyme called methylthioadenosine phosphorylase (MTAP). This study is split into two ...
-
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors
This study is about a new medicine called ICVB-1042 (kills tumor cells) for people with advanced solid tumors. It has two parts: one where we ...
-
AN OPEN-LABEL STUDY OF GV20-0251 IN PATIENTS WITH ADVANCED AND/OR REFRACTORY SOLID TUMOR MALIGNANCIES
This study has two parts, Part A and Part B, and will be testing the drug GV20-0251 to see how well it can help patients ...
-
RevMed RMC-6236-001: A Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Mutations in KRAS at Position G12.
This study is testing a new medicine, RMC-6236, for patients with certain advanced cancers that have specific changes in a gene called RAS. RMC-6236 aims ...
-
A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
You can participate in this study if you are diagnosed with any of the advanced solid tumors found in any of the organ systems. The ...